Somatostatin, a signaling molecule produced by many inhibitory neurons in the brain, broadly dampens communication among a variety of cell types in the prefrontal cortex and promotes exploratory ...

Inhibiting the hormone somatostatin may be a new treatment strategy to prevent dangerous blood glucose drops in type 1 diabetes. This has been shown by a study conducted by the University of ...

Inhibiting the hormone somatostatin may be a new treatment strategy to prevent dangerous blood glucose drops in type 1 diabetes. This has been shown by a study conducted at, among others ...

Although the use of somatostatin and its analogues (octreotide) has been evaluated extensively in high-quality studies (as outlined above) and shown to be effective in adults, this level of ...

Octreotide may extend survival in hepatocellular carcinoma (HCC). Forty-one per cent of HCCs have high-affinity somatostatin receptors. We aimed to determine the feasibility, safety, and activity ...

Researchers have confirmed that neuropeptide somatostatin can improve cognitive function in the brain. A research group of Professor Seung-Hee Lee from the Department of Biological Sciences at ...

Methods: We performed a double-blind randomized trial in 372 consecutive patients undergoing diagnostic or therapeutic ERCP to evaluate the role of somatostatin in preventing post-ERCP pancreatitis.

Somatostatin analogues are medicines that stop your body from making too many hormones. Some neuroendocrine tumours (NETs) make large amounts of hormones. This can cause symptoms. Somatostatin ...

Mycapssa, an oral somatostatin analogue, utilizes a proprietary technology (Transient Permeability Enhancer®), which allows for the development of oral formulations of drugs previously only ...

Pasireotide, a somatostatin analogue that has a longer half-life than octreotide and a broader binding profile, decreases pancreatic exocrine secretions and may prevent postoperative pancreatic ...

Grafton Therapeutics Sarl has identified halogenated somatostatin analogues acting as somatostatin SST2 receptor and/or SST5 receptor agonists reported to be useful for the treatment of cancer.